I've always thought of the company as a joke since they predominantly just try to run trials outside of the U.S. to get approvals for drugs that presumably wouldn't get approved in the U.S. But, I guess they do have a little bit of a revenue stream coming in for Zadaxin for hepatitis B in China. Now, they're trying to develop SCV-07 for a hepatitis C indication.